Follow us for updates
© 2022
Read the Story →

COVID-Flu Joint Booster From Moderna is Due for 2023 Rollout

A single annual booster instead of two.
by Agence France Presse
Jan 18, 2022
Photo/s: Mike Segar, Reuters

GENEVA -- Moderna aims to roll out a combined COVID-flu-RSV booster vaccine in late 2023, the U.S. pharmaceutical firm said Monday, hoping a joint jab would encourage people to get an annual shot.

The single vaccine for COVID-19, influenza and respiratory syncytial virus -- a common virus that causes the cold, but can be more serious for infants and elderly people -- could appear on the market before 2024.

"Best-case scenario will be the fall of '23," Moderna chief executive Stephane Bancel told a virtual World Economic Forum roundtable session.

"I don't think it would happen in every country, but we believe it's possible to happen in some countries next year.

"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter, but to get one dose."

Trials in progress

Bancel said the RSV program was in Phase III trials -- the final stage of human testing -- while the flu program should be entering Phase III in the second quarter of this year.

Continue reading below ↓

Moderna's experimental flu shot, targeting four major strains, is based on the same mRNA method used in its COVID-19 jabs.

The technology provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.


Moderna Confident that Booster Works Against Omicron

Moderna Says COVID Vaccine 93% Effective 4-6 Months After Jab

Got a J&J Vaccine? Study Shows Moderna or Pfizer Booster Works Better

While Moderna's COVID-19 vaccine was based on the original strain of the virus, it was working on finishing an omicron-specific jab within weeks, ahead of trials, said Bancel.

"We're hoping in the March timeframe we should be able to have data to share with regulators to figure out the next step forward."

Hunt for 'holy grail'

Beyond a vaccine specific to omicron -- which is rapidly becoming the world's dominant variant -- laboratories are also pursuing a vaccine that works against all current and future COVID-19 mutations.

Continue reading below ↓
Recommended Videos

"There's some private sector partners that are pursuing it," said Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, which funds vaccine research and development.

"That would be the holy grail because we really don't want to be in position where we're chasing the new variants that are going to come.

"We don't want to be in a position where we're having to vaccinate everybody in the world every three or six months, or even  annually, ideally."

Top U.S. pandemic advisor Anthony Fauci added: "We really don't want to get into the whack-a-mole approach towards every new variant... because you'd be chasing it forever."

Bancel meanwhile said that Moderna had shipped 807 million doses of COVID-19 vaccine in 2021, of which a quarter went to middle- and low-income countries.

Thanks to extra capacity coming on stream before the end of March, the company hopes to be able to make two to three billion doses this year.

Continue reading below ↓

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
Some relief from rising prices.
With the reopening of several local destinations, this app has never been more timely.
Landmark Roe vs Wade ruling of 1973 is overturned.
Its rise mirrors the rise of technology for the masses.
It cites global uncertainties for its move.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.